These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

80 related articles for article (PubMed ID: 11490211)

  • 1. Effect of terazosin on the lipid profile in patients with symptomatic benign prostatic hyperplasia.
    Akbay E; Bozlu M; Doruk E; Akbay E; Cayan S; Ulusoy E
    Urol Int; 2001; 67(2):156-9. PubMed ID: 11490211
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety assessment of terazosin in the treatment of patients with symptomatic benign prostatic hyperplasia: a combined analysis.
    Lowe FC
    Urology; 1994 Jul; 44(1):46-51. PubMed ID: 7518981
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of terazosin on serum lipids.
    Deger G
    Am J Med; 1986 May; 80(5B):82-5. PubMed ID: 2872813
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The impact of medical therapy on bother due to symptoms, quality of life and global outcome, and factors predicting response. Veterans Affairs Cooperative Studies Benign Prostatic Hyperplasia Study Group.
    Lepor H; Williford WO; Barry MJ; Haakenson C; Jones K
    J Urol; 1998 Oct; 160(4):1358-67. PubMed ID: 9751354
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of percent free prostate-specific antigen levels in men with benign prostatic hyperplasia treated with finasteride, terazosin, or watchful waiting.
    Keetch DW; Andriole GL; Ratliff TL; Catalona WJ
    Urology; 1997 Dec; 50(6):901-5. PubMed ID: 9426721
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Evaluation of serum lipid levels in clinical benign prostatic hyperplasia patients with terazosin monotherapy].
    Tamaki M; Ueda T; Kageyama S
    Hinyokika Kiyo; 1999 Dec; 45(12):827-30. PubMed ID: 10659415
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety of combined therapy with terazosin and tolteradine for patients with lower urinary tract symptoms associated with benign prostatic hyperplasia: a prospective study.
    Yang Y; Zhao XF; Li HZ; Wang W; Zhang Y; Xiao H; Zhang X
    Chin Med J (Engl); 2007 Mar; 120(5):370-4. PubMed ID: 17376305
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of branded versus generic terazosin hydrochloride in adults with benign prostatic hyperplasia: a randomized, open-label, crossover study in Taiwan.
    Tsai YS; Lan SK; Ou JH; Tzai TS
    Clin Ther; 2007 Apr; 29(4):670-82. PubMed ID: 17617290
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Alpha 1-adrenoceptor antagonists terazosin and doxazosin induce prostate apoptosis without affecting cell proliferation in patients with benign prostatic hyperplasia.
    Chon JK; Borkowski A; Partin AW; Isaacs JT; Jacobs SC; Kyprianou N
    J Urol; 1999 Jun; 161(6):2002-8. PubMed ID: 10332490
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [A randomized comparative study assessing once versus twice a day treatment of benign prostatic hyperplasia with terazosin].
    Suzuki H; Ohnishi T; Ikemoto I; Ohishi Y; Suzuki Y; Yamazaki H
    Hinyokika Kiyo; 2001 Feb; 47(2):77-81. PubMed ID: 11280890
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy of terazosin and finasteride in symptomatic benign prostatic hyperplasia: A comparative study.
    Anwarul Islam AK; Kashem MA; Shameem IA; Kibria SA
    Bangladesh Med Res Counc Bull; 2005 Aug; 31(2):54-61. PubMed ID: 16967810
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The effects of terazosin and methyclothiazide on blood pressure and serum lipids.
    Luther RR; Glassman HN; Estep CB; Maurath CJ; Jordan DC
    Am Heart J; 1989 Apr; 117(4):842-7. PubMed ID: 2564723
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Terazosin in the treatment of hypertension and symptomatic benign prostatic hyperplasia: a primary care trial.
    Guthrie R
    J Fam Pract; 1994 Aug; 39(2):129-33. PubMed ID: 7520053
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The safety and efficacy of terazosin for the treatment of benign prostatic hyperplasia.
    Lepor H; Knapp-Maloney G; Wozniak-Petrofsky J
    Int J Clin Pharmacol Ther Toxicol; 1989 Aug; 27(8):392-7. PubMed ID: 2477339
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparative evaluation of Prostina and terazosin in the treatment of benign prostatic hyperplasia.
    Dogra PN; Biswas NR; Ravi AK; Mani K; Kumar V
    J Indian Med Assoc; 2005 Feb; 103(2):108-10, 112. PubMed ID: 16008322
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical comparison of selective and non-selective alpha 1A-adrenoceptor antagonists for bladder outlet obstruction associated with benign prostatic hyperplasia: studies on tamsulosin and terazosin in Chinese patients. The Chinese Tamsulosin Study Group.
    Na YJ; Guo YL; Gu FL
    J Med; 1998; 29(5-6):289-304. PubMed ID: 10503165
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of terazosin in the treatment of benign prostatic hyperplasia. A pilot study.
    Dunzendorfer U
    Arzneimittelforschung; 1989 Oct; 39(10):1289-91. PubMed ID: 2482025
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical experience: symptomatic management of BPH with terazosin.
    Dunzendorfer U
    Urology; 1988 Dec; 32(6 Suppl):27-31. PubMed ID: 2462302
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Terazosin: a new antihypertensive agent with favorable effects on lipids.
    Luther RR
    Int J Clin Pharmacol Ther Toxicol; 1989 Jul; 27(7):313-9. PubMed ID: 2570758
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Reduction of human prostate tumor vascularity by the alpha1-adrenoceptor antagonist terazosin.
    Keledjian K; Borkowski A; Kim G; Isaacs JT; Jacobs SC; Kyprianou N
    Prostate; 2001 Jul; 48(2):71-8. PubMed ID: 11433417
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.